Ravuconazole (BMS-207147 and ER-30346) is a potent triazole antifungal being developed by Bristol-Myers Squibb that is currently in phase I/II clinical trials. The drug has a shown to have a similar spectrum of activity to voriconazole with an increased half-life. However ravuconazole has limited activity against species of Fusarium Scedosporium and Zygomycetes.
This page contains content from the copyrighted Wikipedia article "Ravuconazole"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
